You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

48 Items
Cancer Type: Breast     
Intent: Adjuvant, Neoadjuvant, Palliative
Funding:
ODB - General Benefit
    cyclophosphamide - oral tablets
New Drug Funding Program
    Trastuzumab - Adjuvant Treatment for HER2_neu-Overexpressing Primary Breast Cancer
Evidence Building Program
    Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer
New Drug Funding Program
    Trastuzumab - Second Line - Metastatic Breast Cancer
May 2019
Cancer Type: Skin, Melanoma     
Intent: Palliative
Funding:
Exceptional Access Program
    cobimetinib - For combination therapy (with vemurafenib) for the treatment of patients with previously untreated BRAF V600 mutation-positive unresectable stage III or IV melanoma
Exceptional Access Program
    vemURAFenib- For combination therapy (with cobimetinib) for the treatment of patients with previously untreated BRAF V600 mutation-positive unresectable stage Ill or stage IV melanoma
May 2019
Cancer Type: Breast     
Intent: Curative, Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab - Adjuvant Treatment for HER2_neu-Overexpressing Primary Breast Cancer
New
Nov 2019
Cancer Type: Breast     
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab - Adjuvant Treatment for HER2_neu-Overexpressing Primary Breast Cancer
Evidence Building Program
    Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer
Oct 2019
Cancer Type: Gastrointestinal, Esophagus, Gastric / Stomach     
Intent: Palliative
Drugs Used:
trastuzumab (PDRP prior authorization),
Updated
Nov 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Aug 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Funding:
New Drug Funding Program
    Pemetrexed - Combination with Platinum for Non-Small Cell Lung Cancer
Updated
Nov 2019
Cancer Type: Breast     
Intent: Adjuvant
Funding:
New Drug Funding Program
    Docetaxel - CYCLDOCE for Early Operable Breast Cancer
New Drug Funding Program
    Trastuzumab - Adjuvant Treatment for HER2_neu-Overexpressing Primary Breast Cancer
Evidence Building Program
    Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer
Evidence Building Program
    Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer Supplemental
Feb 2019
Cancer Type: Breast     
Intent: Palliative
Funding:
New Drug Funding Program
    Pertuzumab-Trastuzumab - Unresectable Locally Recurrent or Metastatic - Breast Cancer
New Drug Funding Program
    Docetaxel - Metastatic Breast Cancer
Aug 2017
Cancer Type: Breast     
Intent: Palliative
Funding:
New Drug Funding Program
    Docetaxel - Metastatic Breast Cancer
New Drug Funding Program
    Trastuzumab in Combination with Docetaxel - Metastatic Breast Cancer
New Drug Funding Program
    Trastuzumab - Second Line - Metastatic Breast Cancer
Jul 2019
Cancer Type: Breast     
Intent: Curative, Adjuvant
Funding:
New Drug Funding Program
    Docetaxel - FEC-D or AC-DOCE for Adjuvant Treatment for Breast Cancer
New Drug Funding Program
    Epirubicin - Adjuvant Treatment for Breast Cancer
New Drug Funding Program
    Trastuzumab - Adjuvant Treatment for HER2_neu-Overexpressing Primary Breast Cancer
New
Nov 2019
Cancer Type: Breast     
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
  • Docetaxel - Neoadjuvant treatment for Non-Metastatic Breast Cancer
New Drug Funding Program
  • Docetaxel - FEC-D or AC-DOCE for Adjuvant Treatment for Breast Cancer
New Drug Funding Program
  • Epirubicin - Neoadjuvant Treatment for Non-Metastatic Breast Cancer
New Drug Funding Program
  • Epirubicin - Adjuvant Treatment for Breast Cancer
New Drug Funding Program
  • Trastuzumab - Adjuvant Treatment for HER2_neu-Overexpressing Primary Breast Cancer
Feb 2019